BPS Bioscience Inc. published an application note demonstrating how recombinant TIGIT, CD155, and CD226 proteins perform in HTRF-based protein–protein interaction assays.
Published
Signal category
Research & Knowledge
Quote
“This application note from BPS Bioscience demonstrates how recombinant TIGIT, CD155, and CD226 proteins perform in HTRF-based protein–protein interaction assays”
— Ali Yehia|BPS Bioscience Inc. team
Company
BPS Bioscience Inc.
Scientist Founded, Scientist Driven
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 111 employees
BPS Bioscience advances new scientific discoveries that lead to therapies by creating innovative solutions for research. Our focus areas are immunotherapy, epigenetics, neuroscience, CRISPR, cell signaling, and more, providing 4000+ high quality recombinant cell lines, lentiviruses, proteins, and assays. We can supply products in bulk quantities, as well as customize our manufacturing. We also offer biochemical and cell-based screening services to accelerate your research. By being at the forefront of technology development, we provide quality life science products and services in a timely manner that accelerate drug discovery and development for the treatment of human diseases. to learn more, visit our website at bpsbioscience.com.